Skip to main content

Table 3 Changes in the prevalence rates of metabolic syndrome and its components within and between groups

From: Impact of postpartum weight change on metabolic syndrome and its components among women with recent gestational diabetes mellitus

 

Weight loss > 2 kg (n = 30)

Weight stability ± 2 kg (n = 85)

Weight gain > 2 kg (n = 56)

 
 

6 weeks

6 months

Change

p-valuea

6 weeks

6 months

Change

p-valuea

6 weeks

6 months

Change

p-valuea

p-valueb

MetSc

11 (36.7)

5 (16.7)

− 6 (− 20.0)d,e

0.031

12 (14.1)

22 (25.9)

10 (11.8)

0.013

17 (30.4)

25 (44.6)

8 (14.2)

0.049

0.002

 Large WC

20 (66.7)

12 (40.0)

− 8 (− 26.7)d,e

0.008

54 (63.5)

49 (57.6)

− 5 (− 5.9)

0.227

41 (73.2)

44 (78.6)

3 (5.4)

0.375

0.004

 Elevated BP

6 (20.0)

2 (6.7)

− 4 (− 13.3)

0.219

17 (20.0)

13 (15.3)

 − 4 (4.7)

0.454

17 (30.4)

16 (28.6)

− 1 (− 1.8)

1.000

0.172

 Elevated FPG

5 (16.7)

4 (13.3)

− 1 (− 3.4)d,e

1.000

11 (12.9)

27 (31.8)

16 (18.9)

< 0.001

11 (19.6)

26 (46.4)

15 (26.8)

< 0.001

0.022

 High TG

11 (36.7)

2 (6.7)

− 9 (− 30.0)e

0.004

22 (25.9)

22 (25.9)

0 (0)

1.000

23 (41.1)

19 (33.9)

− 4 (− 7.2)

0.454

0.024

 Low HDL-C

11 (36.7)

9 (30.0)

− 2 (− 6.7)

0.687

18 (21.2)

28 (32.9)

10 (11.7)

0.064

20 (35.7)

27 (48.2)

7 (12.5)

0.092

0.389

  1. Data are presented as n (%)
  2. BP blood pressure, FPG fasting plasma glucose, HDL-C high-density lipoprotein cholesterol, MetS metabolic syndrome, TG triglycerides, WC waist circumference
  3. aChanges over time within a group were analyzed using McNemar’s test
  4. bChanges between groups were analyzed with the chi-squared test
  5. cComponents of MetS include (1) large WC (≥ 80 cm), (2) elevated BP (systolic BP ≥ 130 mmHg, diastolic BP ≥ 85 mmHg, or both, or treatment with antihypertensive drugs), (3) elevated FPG levels (≥ 100 mg/dL or treatment with antidiabetic medications), (4) high TG levels (≥ 150 mg/dL or treatment with drugs for elevated TG levels), and (5) low HDL-C levels (< 50 mg/dL or drug treatment for reduced HDL-C levels)
  6. dp < 0.05, compared with the weight gain group
  7. ep < 0.05, compared with the weight stability group